Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.40 |
| ▸ | CCR1 | P32246 | 3/20 | 0.37 |
| ▸ | CCR2 | P41597 | 3/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.34 |
| ▸ | PER2 | O15055 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990822 | 0.86 | HSD11B1 (0.54) | HSD11B1OPRM1P2RX7ALDH1A1 | |
| SCHEMBL209282 | 0.84 | HSD11B1 (0.52) | HSD11B1P2RX7ALDH1A1 | |
| SCHEMBL4517502 | 0.82 | HSD11B1 (0.62) | HSD11B1OPRM1ALDH1A1 | |
| SCHEMBL3543212 | 0.82 | HSD11B1 (0.68) | HSD11B1ALDH1A1 | |
| SCHEMBL210897 | 0.82 | HSD11B1 (0.49) | HSD11B1OPRM1 | |
| SCHEMBL2991334 | 0.81 | HSD11B1 (0.47) | HSD11B1OPRM1P2RX7ALDH1A1 | |
| SCHEMBL4514748 | 0.80 | HSD11B1 (0.74) | HSD11B1ALDH1A1 | |
| SCHEMBL4697246 | 0.79 | HSD11B1 (0.61) | HSD11B1OPRM1ALDH1A1 | |
| SCHEMBL3547913 | 0.78 | HSD11B1 (0.67) | HSD11B1ALDH1A1 | |
| SCHEMBL3545096 | 0.78 | HSD11B1 (0.66) | HSD11B1PER2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885OPRM1 3446/4885CCR1 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.